Mortality and drug exposure in a 5-year cohort of patients with chronic liver disease

Swiss Medical Weekly

Volumn 139, Issue 51-52, 2009, Pages 737-746

  Hug, Balthasar L ^a   Lipsitz, Stuart R ^a   Seger, Diane L ^a   Karson, Andrew S ^b   Wright, Steven C ^c   Bates, David W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Brigham and Women's/Faulkner Hospitals   (United States)

Author keywords

Ambulatory; Chronic liver disease; Cirrhosis; Drug exposure; Hospitalised; MELD score; Mortality; Secondary referral hospital; Tertiary referral hospital

Indexed keywords

ACETAZOLAMIDE; AMIODARONE; ANTINEOPLASTIC AGENT; ATORVASTATIN; AZATHIOPRINE; BILIRUBIN; CREATININE; CYCLOSPORIN A; DOCETAXEL; ETOPOSIDE; IBUPROFEN; LAMIVUDINE; METFORMIN; MORPHINE; PRAVASTATIN; RAPAMYCIN; SIMVASTATIN;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC LIVER DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EXPOSURE; FEMALE; HEPATITIS C; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIVER CIRRHOSIS; LIVER METABOLISM; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATIENT REFERRAL; SURVIVAL RATE; TERTIARY HEALTH CARE;

EID: 74549195007     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Minino AM HM, Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep. 2006;54:1-49.
2. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-6.
3. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. (Baltimore, Md 2000;31:864-71.
4. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-9.
5. Schmidt LE, Larsen FS. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology. (Baltimore, Md 2007;45:789-96.
6. Teh SH, Nagorney DM, Stevens SR, et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology. 2007;132:1261-9.
7. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. (Baltimore, Md 2001;33:464-70.
8. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10:1018-23.
9. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-54.
10. Murphy SN, Chueh HC. A security architecture for query tools used to access large biomedical databases. Proc AMIA Symp. 2002:552-6.
11. Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Population health metrics 2006;4:2.
12. Schisterman EF, Whitcomb BW. Use of the Social Security Administration Death Master File for ascertainment of mortality status. Population health metrics 2004;2:2.
13. Lin DW LY. Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals. Biometrika. 1993;80:557-72.
14. Bjornsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis. 2006;38:33-8.
15. Filippi L, Bagnoli F, Margollicci M, Zammarchi E, Tronchin M, Rubaltelli FF. Pathogenic mechanism, prophylaxis, and therapy of symptomatic acidosis induced by acetazolamide. J Investig Med. 2002;50:125-32.
16. Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl. 2005;11:267-80.
17. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38 (Suppl 2):S44-8.
18. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731-9.
19. Stricker BH, Blok AP, Babany G, Benhamou JP. Fibrin ring granulomas and allopurinol. Gastroenterology. 1989;96:1199-203.
20. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Seminars in liver disease. 2002;22:169-83.
21. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. (British Cardiac Society) 2007;93:914-21.
22. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:2307-13.
23. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516-20.
24. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology. (Cambridge, Mass 2001;12:682-9.
25. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512-21.
26. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. (Baltimore, Md 2005;42:481-9.
27. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 2005;11:281-9.
28. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12:462-8.
29. http://www.ntis.gov/products/pages/ssa-death-master.asp.2007.
30. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40:897-903.
31. Avorn J. In defense of pharmacoepidemiology - embracing the yin and yang of drug research. N Engl J Med. 2007;357:2219-21.
32. Sturmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005;161:891-8.
33. Stanley K. Evaluation of randomized controlled trials. Circulation. 2007;115:1819-22.